Based on its sound industrial ecosystem and strong policy support, Zhangjiang Pharma Valley in Shanghai is witnessing accelerated development in cutting-edge technologies such as innovative medical devices, artificial intelligence-based drug research and development, and synthetic biology, said industry mavens.
Surgical robot company Shanghai MicroPort MedBot reached a milestone in the first half of the year, as new orders for its Toumai surgical robots surpassed the long dominance of an overseas brand for the first time. As of June, Toumai robots had received over 300 cumulative orders from Asia, Europe, Latin America, the Middle East and Africa, while the number of cumulative installations has exceeded 200 units.
As the world's first and only remotely operated surgical platform to receive regulatory approval, Toumai remote surgical robots have obtained a green light in more than 50 countries and regions.
According to Li Shuxiang, vice-president of MicroPort MedBot, surgical robots integrate the disciplines of precision mechanics, AI, medical imaging, control algorithms and clinical medicine. As they involve longer research cycles and high technical barriers, they are more demanding of innovation resources.
